Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CEBPE
REST API REST API
Homo sapiens
CEBPE is differentially expressed in 149 experiments: 56 organism parts: bone marrow, ovary, ... (54 more);, 109 disease states: normal, acute lymphoblastic leukemia, ... (107 more);, 41 cell types 96 cell lines 14 compound treatments and 59 other conditions.
Synonyms CRP1
Orthologs F6WQL4_CIOIN (Ciona intestinalis)   Cebpe (Rattus norvegicus)   E1BDB7_BOVIN (Bos taurus)   Cebpe (Mus musculus)   slbo (Drosophila melanogaster)   cebpe (Xenopus laevis)   CEBPE (Canis familiaris)   (Compare orthologs)
InterPro Term bZIP_1, bZIP_2, TF_bZIP, CCAAT/enhancer-binding
Gene Ontology Term DNA binding, regulation of transcription, DNA-dependent, phagocytosis, sequence-specific DNA binding, defense response, protein dimerization activity, nucleus, defense response to bacterium, protein heterodimerization activity, protein homodimerization activity, cytokine biosynthetic process, macrophage differentiation, cellular response to lipopolysaccharide, myeloid cell differentiation, sequence-specific DNA binding transcription factor activity
UniProt Accession Q15744
Gene-Disease Assocation SPECIFIC GRANULE DEFICIENCY; SGD
Search EB-eye ENSG00000092067
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-803, E-MTAB-24, E-GEOD-7540, ... (17 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-1880, E-GEOD-22152, E-GEOD-22639, E-GEOD-19639, ... (18 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
Jurkat
2
E-GEOD-1880, E-MTAB-62
NCIH69
1
E-MTAB-37
Hmec-1
1
E-MTAB-62
T98G glioma
1
E-GEOD-4219
CCRFCEM
1
E-MTAB-37
90 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-3920, E-GEOD-20677, E-GEOD-13987, E-GEOD-11755, ... (26 experiments)

Factor Value U/D Experiments
stromal cell
2
E-GEOD-10797, E-GEOD-1460
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
CD56+ NK cells
1
1
E-AFMX-5
B cell
2
1
E-GEOD-13987
epidermal keratinocyte
1
E-GEOD-2822
spermatid
1
E-TABM-130
35 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-2069, E-GEOD-22148, ... (31 experiments)

Factor Value U/D Experiments
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
acute promyelocytic leukemia
2
E-GEOD-995, E-MTAB-62
hepatitis c
1
E-MTAB-62
osteosarcoma
1
E-MTAB-62
leiomyosarcoma
1
E-MTAB-62
lung carcinoma
1
E-GEOD-6014
103 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-7400, E-GEOD-3284, E-GEOD-412, E-GEOD-3720, ... (12 experiments)

Factor Value U/D Experiments
none
2
5
E-GEOD-5824, E-GEOD-995, E-GEOD-7400, E-GEOD-412, E-GEOD-7307, ... (7 experiments)
actinomycin D
1
1
E-GEOD-6400
Cxcl12
1
E-GEOD-7307
not specified
1
E-GEOD-20081
rapamycin
1
E-GEOD-5824
unknown
1
E-GEOD-7307
8 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-2171, E-GEOD-16363, E-GEOD-1725, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-860, E-GEOD-16363

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-3140, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023

Genotype
studied in E-GEOD-2466, E-TABM-321, E-TABM-868, E-MEXP-1838, E-MEXP-1403 ... (5 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-MEXP-1446, E-MEXP-2146

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-GEOD-2466, E-TABM-666, ... (22 experiments)

Infection
studied in E-GEOD-12254, E-GEOD-9723, E-MEXP-561, E-GEOD-980

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-22152, E-GEOD-1657, E-GEOD-1460, E-GEOD-7114, E-MEXP-1403 ... (5 experiments)

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19246

Replicate
studied in E-GEOD-10797

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-2466, E-GEOD-21521

Stimulation
studied in E-GEOD-20114, E-GEOD-11886

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Processing time: 0.493 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM